Phantom EBITDA

The playbook exists. One side has it. Now the other side does too.

Every year, dental practice owners walk into acquisition meetings having spent decades building something real - and walk out with a number that reflects what a buyer could negotiate, not what the practice was worth.

The mechanism is not mystery. It is information asymmetry.

Private equity enters every dental acquisition with a QoE team, a payer mix model, and a forensic audit protocol built on one assumption: the seller doesn't have the same data. They're usually right. The practice owner has a CPA who reads the P&L. The buyer has an analyst who reads the Practice Management Software. That gap - between what the financials show and what the clinical data reveals - is where deals get re-traded after the LOI is signed and the seller has surrendered their leverage.

Phantom EBITDA names the mechanism precisely: the revenue that appears defensible on a P&L but evaporates under a Quality of Earnings audit, enabling buyers to compress valuations after exclusivity is signed and the seller cannot walk away.

This book documents:

• How PE buyers extract, benchmark, and weaponize your own PMS data against you


• The specific clinical compliance findings - D2950 overbilling, hygiene code alternation, payer collection anomalies - that destroy EBITDA at the closing table


• Why the five-year PMS look-back reveals what your three-year P&L cannot hide


• The behavioral signals - refund history patterns, undocumented clinical changes, escheatment liability - that sophisticated buyers flag before you know they're looking


• How to build a Defensible Data Room years before a transaction - and why starting early is the only thing that actually changes your multiple


• The Pre-LOI Forensic Sanitization process: running your own hostile audit before a buyer does, and using the findings to build an institutionally auditable asset that commands a premium